{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:01:42Z","timestamp":1790625702750,"version":"4.1.0"},"reference-count":188,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44AI124766, R44AI129147"],"award-info":[{"award-number":["R44AI124766, R44AI129147"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician\u2019s view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.<\/jats:p>","DOI":"10.3390\/jcm8040493","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T03:46:37Z","timestamp":1555040797000},"page":"493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes"],"prefix":"10.3390","volume":"8","author":[{"given":"Lukasz S.","family":"Wylezinski","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"},{"name":"IQuity, Inc., Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamieson D.","family":"Gray","sequence":"additional","affiliation":[{"name":"IQuity, Inc., Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Polk","sequence":"additional","affiliation":[{"name":"IQuity, Inc., Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Harmata","sequence":"additional","affiliation":[{"name":"IQuity, Inc., Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles F.","family":"Spurlock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA"},{"name":"IQuity, Inc., Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Feehan, K.T., and Gilroy, D.W. (2019). Is Resolution the End of Inflammation?. Trends Mol. Med.","DOI":"10.1016\/j.molmed.2019.01.006"},{"key":"ref_2","first-page":"319201","article-title":"Adding to the burden: Gastrointestinal symptoms and syndromes in multiple sclerosis","volume":"2013","author":"Levinthal","year":"2013","journal-title":"Mult. Scler. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: Time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.rdc.2010.02.002","article-title":"Cardiovascular complications of rheumatoid arthritis: Assessment, prevention, and treatment","volume":"36","author":"Kaplan","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1373\/clinchem.2012.189480","article-title":"Autoimmune diseases: Early diagnosis and new treatment strategies","volume":"58","author":"Konforte","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nrendo.2013.161","article-title":"Clinical implications of shared genetics and pathogenesis in autoimmune diseases","volume":"9","author":"Zhernakova","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00108-005-1371-3","article-title":"Early diagnosis of chronic systemic inflammatory disorders","volume":"46","author":"Hellmich","year":"2005","journal-title":"Internist"},{"key":"ref_8","first-page":"379","article-title":"The diagnosis of exclusion: An ongoing uncertainty","volume":"40","author":"Fred","year":"2013","journal-title":"Tex. Heart Inst. J."},{"key":"ref_9","first-page":"755","article-title":"A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation","volume":"19","author":"Nellesen","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.3748\/wjg.v23.i35.6474","article-title":"Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery","volume":"23","author":"Lee","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3904\/kjim.2017.213","article-title":"Impact of early diagnosis on functional preservation in patients with rheumatoid arthritis: The early bird catches the worm","volume":"32","author":"Cheon","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","article-title":"Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases","volume":"8","author":"Sandborn","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp-2017-317509","article-title":"Time matters in multiple sclerosis: Can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?","volume":"89","author":"Cerqueira","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: An update","volume":"30","author":"Zarco","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_15","unstructured":"Wallin, M.T. (2017, January 25\u201328). The Prevalence of Multiple Sclerosis in the United States: A Population-Based Healthcare Database Approach. Proceedings of the ECTRIMS, Paris, France."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ncl.2017.08.007","article-title":"Ethnic Considerations and Multiple Sclerosis Disease Variability in the United States","volume":"36","author":"Amezcua","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohn\u2019s disease and ulcerative colitis in the United States","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","article-title":"Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004\u20132014","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_20","first-page":"415","article-title":"The comparative economic burden of mild, moderate, and severe fibromyalgia: Results from a retrospective chart review and cross-sectional survey of working-age U.S. adults","volume":"18","author":"Chandran","year":"2012","journal-title":"J. Manag. Care Pharm."},{"key":"ref_21","first-page":"71","article-title":"The epidemiology of irritable bowel syndrome","volume":"6","author":"Canavan","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","article-title":"Incidence and Prevalence of Crohn\u2019s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010","volume":"15","author":"Shivashankar","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955\u20132007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.rhu.0000221817.46231.18","article-title":"The incidence of fibromyalgia and its associated comorbidities: A population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes","volume":"12","author":"Weir","year":"2006","journal-title":"J. Clin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11910-013-0403-y","article-title":"Misdiagnosis of multiple sclerosis: Frequency, causes, effects, and prevention","volume":"13","author":"Solomon","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5217\/ir.2016.14.3.258","article-title":"Change in the diagnosis of inflammatory bowel disease: A hospital-based cohort study from Korea","volume":"14","author":"Lee","year":"2016","journal-title":"Intest. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-017-0630-4","article-title":"Whipple\u2019s disease mimicking rheumatoid arthritis can cause misdiagnosis and treatment failure","volume":"12","author":"Glaser","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Walitt, B., Katz, R.S., Bergman, M.J., and Wolfe, F. (2016). Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157235"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/2050640614554217","article-title":"Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database","volume":"2","author":"Card","year":"2014","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_30","first-page":"47","article-title":"Advances in the treatment of relapsing-remitting multiple sclerosis: The role of pegylated interferon \u03b2-1a","volume":"7","author":"Furber","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"19","article-title":"Diagnosis and differential diagnosis of multiple sclerosis","volume":"16","author":"Cree","year":"2010","journal-title":"Continuum"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7224\/1537-2073.2017-069","article-title":"Somatic Symptoms of Depression and Anxiety in People with Multiple Sclerosis","volume":"20","author":"Jones","year":"2018","journal-title":"Int. J. MS Care"},{"key":"ref_34","first-page":"511","article-title":"Functional Somatic Syndrome: Assessment and Management","volume":"117","author":"Graver","year":"2017","journal-title":"J. Am. Osteopath Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.7224\/1537-2073.2016-069","article-title":"Triaging Patients with Multiple Sclerosis in the Emergency Department: Room for Improvement","volume":"19","author":"Abboud","year":"2017","journal-title":"Int. J. MS Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2017.03.014","article-title":"Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants","volume":"81","author":"Aune","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/hmg\/ddt267","article-title":"Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls","volume":"22","author":"Nickles","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000393","article-title":"Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents","volume":"39","author":"Caldano","year":"2017","journal-title":"Drug Monit."},{"key":"ref_41","unstructured":"Tice, J.A., Chapman, R., Kumar, V., Loos, A.M., Liu, S., Seidner, M., Ollendorf, D.A., Rind, D., Pearson, S.D., and Zimmermann, M. (2017). Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value, Institute for Clinical and Economic Review, California Technology Assessment Forum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: Safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"Clin. Outcomes Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/PROM.S148387","article-title":"Comorbidity in US patients with multiple sclerosis","volume":"9","author":"Edwards","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s13311-017-0563-6","article-title":"Wellness and the Role of Comorbidities in Multiple Sclerosis","volume":"14","author":"Moss","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1212\/01.wnl.0000333252.78173.5f","article-title":"Comorbidity delays diagnosis and increases disability at diagnosis in MS","volume":"72","author":"Marrie","year":"2009","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MRR.0b013e32834ad479","article-title":"Quality of life in patients with multiple sclerosis: The impact of depression, fatigue, and disability","volume":"34","author":"Kaya","year":"2011","journal-title":"Int. J. Rehabil. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/11314700-000000000-00000","article-title":"The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US","volume":"27","author":"Ivanova","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jval.2012.07.010","article-title":"Work productivity in relapsing multiple sclerosis: Associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life","volume":"15","author":"Glanz","year":"2012","journal-title":"Value Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2013.04.007","article-title":"Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers","volume":"330","author":"Lefebvre","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11894-001-0068-6","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"3","author":"Bernstein","year":"2001","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0016-5085(79)90389-5","article-title":"Clinical features and natural history of Crohn\u2019s disease","volume":"77","author":"Mekhjian","year":"1979","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1111\/j.1572-0241.2000.03361.x","article-title":"Identification of a prodromal period in Crohn\u2019s disease but not ulcerative colitis","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","article-title":"An Update on Inflammatory Bowel Disease","volume":"44","author":"Sairenji","year":"2017","journal-title":"Prim Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5946\/ce.2016.090","article-title":"Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease","volume":"49","author":"Lee","year":"2016","journal-title":"Clin. Endosc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3748\/wjg.v21.i1.21","article-title":"Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives","volume":"21","author":"Tontini","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.gie.2006.02.005","article-title":"ASGE guideline: Endoscopy in the diagnosis and treatment of inflammatory bowel disease","volume":"63","author":"Leighton","year":"2006","journal-title":"Gastrointest. Endosc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3810\/pgm.2010.07.2184","article-title":"Serologic markers: Impact on early diagnosis and disease stratification in inflammatory bowel disease","volume":"122","author":"Arai","year":"2010","journal-title":"Postgrad. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7451946","DOI":"10.1155\/2018\/7451946","article-title":"Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases","volume":"2018","author":"Derkacz","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.11613\/BM.2013.006","article-title":"Serological markers of inflammatory bowel disease","volume":"23","author":"Kuna","year":"2013","journal-title":"Biochem. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.14309\/00000434-201802001-00106","article-title":"Long, Non-coding RNA Gene Expression Signatures to Distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease","volume":"113","author":"Tossberg","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chudy-Onwugaje, K.O., Christian, K.E., Farraye, F.A., and Cross, R.K. (2018). A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm. Bowel Dis.","DOI":"10.1093\/ibd\/izy327"},{"key":"ref_65","unstructured":"Wilhelm, S.M., and Love, B.L. (2017). Management of Patients with Inflammatory Bowel Disease: Current and Future Treatments. Pharm. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/0016-5085(92)91163-X","article-title":"Colorectal cancer risk and mortality in patients with ulcerative colitis","volume":"103","author":"Langholz","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gut.2010.234617","article-title":"Surgery for adult Crohn\u2019s disease: What is the actual risk?","volume":"60","author":"Bouguen","year":"2011","journal-title":"Gut"},{"key":"ref_68","first-page":"749","article-title":"Ulcerative colitis: A challenge to surgeons","volume":"3","author":"Parray","year":"2012","journal-title":"Int. J. Prev. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2036.2004.02053.x","article-title":"Review article: patients\u2019 fears and unmet needs in inflammatory bowel disease","volume":"20","author":"Irvine","year":"2004","journal-title":"Aliment Pharm. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","article-title":"Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn\u2019s disease","volume":"30","author":"Reilly","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00054725-200211000-00002","article-title":"The impact of inflammatory bowel disease on labor force participation: Results of a population sampled case-control study","volume":"8","author":"Boonen","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3109\/00365529709002993","article-title":"Inflammatory bowel diseases: Health care and costs in Sweden in 1994","volume":"32","author":"Blomqvist","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","article-title":"Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013\u20132015","volume":"66","author":"Barbour","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3756207","DOI":"10.1155\/2018\/3756207","article-title":"Work Ability and Employment in Rheumatoid Arthritis: A Cross-Sectional Study on the Role of Muscle Strength and Lower Extremity Function","volume":"2018","author":"Berner","year":"2018","journal-title":"Int. J. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of Rheumatoid Arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.18773\/austprescr.2015.034","article-title":"Erythrocyte sedimentation rate and C-reactive protein","volume":"38","author":"Harrison","year":"2015","journal-title":"Aust. Prescr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","first-page":"27","article-title":"Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends","volume":"10","author":"Atzinger","year":"2017","journal-title":"Am. Health Drug Benefits"},{"key":"ref_81","unstructured":"Murphy, J.E., and Wun-Len Lee, M. (2014). Biologic Disease-Modifying Anti-rheumatic Drugs. Pharmacotherapy Self-Assessment Program\u2014Chronic Illnesses I, American Collage of Clinical Pharmacy."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5312\/wjo.v6.i2.278","article-title":"Is non-biological treatment of rheumatoid arthritis as good as biologics?","volume":"6","author":"Parida","year":"2015","journal-title":"World J. Orthop."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.berh.2007.05.006","article-title":"The course of established rheumatoid arthritis","volume":"21","author":"Scott","year":"2007","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.coph.2011.09.009","article-title":"The shifting interface between IBS and IBD","volume":"11","author":"Spiller","year":"2011","journal-title":"Curr. Opin. Pharm."},{"key":"ref_85","first-page":"58","article-title":"Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register","volume":"37","author":"Provan","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1352458514564488","article-title":"The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"ref_87","first-page":"814","article-title":"Fibrositis (Fibromyalgia) in rheumatoid arthritis","volume":"11","author":"Wolfe","year":"1984","journal-title":"J. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.61.7.660","article-title":"Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability","volume":"61","author":"Naranjo","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/1756-185X.13055","article-title":"Fibromyalgia remains a significant burden in rheumatoid arthritis patients in Australia","volume":"21","author":"Gist","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","article-title":"Concomitant fibromyalgia complicating chronic inflammatory arthritis: A systematic review and meta-analysis","volume":"57","author":"Duffield","year":"2018","journal-title":"Rheumatology"},{"key":"ref_91","first-page":"S35","article-title":"Evidence-based management of irritable bowel syndrome with diarrhea","volume":"24","author":"Pimentel","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable Bowel Syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/ajg.2016.574","article-title":"Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome","volume":"112","author":"Sayuk","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17550","article-title":"Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: Systematic review and economic evaluation","volume":"17","author":"Waugh","year":"2013","journal-title":"Health Technol. Assess."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ajg.2012.260","article-title":"Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis","volume":"107","author":"Halpin","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOG.0000000000000070","article-title":"Inflammatory bowel disease and irritable bowel syndrome: Similarities and differences","volume":"30","author":"Barbara","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e13483","DOI":"10.1111\/nmo.13483","article-title":"Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study","volume":"31","author":"Polster","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_98","unstructured":"Mearin, F., Lacy, B.E., Chang, L., Chey, W.D., Lembo, A.J., Simren, M., and Spiller, R. (2016). Bowel Disorders. Gastroenterology."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.JAA.0000553384.82884.b8","article-title":"Nonpharmacologic options for treating irritable bowel syndrome","volume":"32","author":"Kay","year":"2019","journal-title":"JAAPA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5056\/jnm16001","article-title":"The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments","volume":"22","author":"Farzaei","year":"2016","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_102","unstructured":"Grover, S. (2019). Treatment of Irritable Bowel Syndrome in Adults, UptoDate."},{"key":"ref_103","unstructured":"Lexicomp (2019). Alosetron: Drug Information, UptoDate."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/apt.12938","article-title":"Review article: The economic impact of the irritable bowel syndrome","volume":"40","author":"Canavan","year":"2014","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jwh.2011.3029","article-title":"Development and testing of the fibromyalgia diagnostic screen for primary care","volume":"21","author":"Arnold","year":"2012","journal-title":"J. Womens Health"},{"key":"ref_108","first-page":"S104","article-title":"Misdiagnosis in fibromyalgia: A multicentre study","volume":"29","author":"Iannuccelli","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/keg075","article-title":"Inaccuracy in the diagnosis of fibromyalgia syndrome: Analysis of referrals","volume":"42","author":"Fitzcharles","year":"2003","journal-title":"Rheumatology"},{"key":"ref_110","first-page":"2","article-title":"Pain management in rheumatology research, training, and practice","volume":"35","author":"Borenstein","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Perrot, S., Choy, E., Petersel, D., Ginovker, A., and Kramer, E. (2012). Survey of physician experiences and perceptions about the diagnosis and treatment of fibromyalgia. BMC Health Serv. Res., 12.","DOI":"10.1186\/1472-6963-12-356"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Choy, E., Perrot, S., Leon, T., Kaplan, J., Petersel, D., Ginovker, A., and Kramer, E. (2010). A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv. Res., 10.","DOI":"10.1186\/1472-6963-10-102"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2012.02.010","article-title":"A framework for fibromyalgia management for primary care providers","volume":"87","author":"Arnold","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.mayocp.2016.02.002","article-title":"Opioid Use in Fibromyalgia: A Cautionary Tale","volume":"91","author":"Goldenberg","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/papr.12364","article-title":"Evaluating Guideline-recommended Pain Medication Use Among Patients with Newly Diagnosed Fibromyalgia","volume":"16","author":"Halpern","year":"2016","journal-title":"Pain Pract."},{"key":"ref_116","first-page":"e177","article-title":"Healthcare Costs Associated With Chronic Opioid Use and Fibromayalgia Syndrome","volume":"6","author":"Painter","year":"2014","journal-title":"Am. J. Pharm. Benefits"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1529-0131(200002)13:1<42::AID-ART7>3.0.CO;2-R","article-title":"Quality of life issues for fibromyalgia patients","volume":"13","author":"Bernard","year":"2000","journal-title":"Arthritis Care Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.whi.2008.04.005","article-title":"Self-assessed physical function levels of women with fibromyalgia: A national survey","volume":"18","author":"Jones","year":"2008","journal-title":"Womens Health Issues"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Kassam, A., and Patten, S.B. (2006). Major depression, fibromyalgia and labour force participation: A population-based cross-sectional study. BMC Musculoskelet. Disord., 7.","DOI":"10.1186\/1471-2474-7-4"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1573397113666170502152955","article-title":"Work Ability in Fibromyalgia: An Update in the 21st Century","volume":"13","author":"Palstam","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Cortaredona, S., and Ventelou, B. (2017). The extra cost of comorbidity: Multiple illnesses and the economic burden of non-communicable diseases. BMC Med., 15.","DOI":"10.1186\/s12916-017-0978-2"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/MEG.0000000000000891","article-title":"Chronic comorbidities associated with inflammatory bowel disease: Prevalence and impact on healthcare costs in Switzerland","volume":"29","author":"Schoepfer","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","article-title":"Comorbidity in inflammatory bowel disease","volume":"17","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11606-011-1704-y","article-title":"Depression and medication adherence in the treatment of chronic diseases in the United States: A meta-analysis","volume":"26","author":"Grenard","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3892\/etm.2016.3966","article-title":"Risk of cardiovascular disease in inflammatory bowel disease","volume":"13","author":"Wu","year":"2017","journal-title":"Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.24836","article-title":"Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study","volume":"61","author":"Peters","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/ard.61.4.290","article-title":"Early referral recommendation for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide","volume":"61","author":"Emery","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: Efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Adv. Musculoskelet. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4291\/wjgp.v7.i1.1","article-title":"Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy","volume":"7","author":"Cintolo","year":"2016","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: An open randomised trial","volume":"371","author":"Baert","year":"2008","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000490053","article-title":"The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives","volume":"2","author":"Arnott","year":"2018","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/1319-3767.129473","article-title":"Advances in the diagnosis and management of inflammatory bowel disease: Challenges and uncertainties","volume":"20","author":"Mosli","year":"2014","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_140","unstructured":"Solomon, A.J., Naismith, R.T., and Cross, A.H. (2018). Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice. Neurology."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","article-title":"Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Results from the Danish nationwide DANBIO registry","volume":"74","author":"Hetland","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/ecco-jcc\/jjx041","article-title":"The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study","volume":"11","author":"Cantoro","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/art.1780370606","article-title":"The lag time between onset of symptoms and diagnosis of rheumatoid arthritis","volume":"37","author":"Chan","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Barin, L., Kamm, C.P., Salmen, A., Dressel, H., Calabrese, P., Pot, C., Schippling, S., Gobbi, C., Muller, S., and Chan, A. (2019). How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. Mult. Scler. J.","DOI":"10.1177\/1352458518823955"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Gallinger, Z., Ungaro, R., Colombel, J.-F., Sandler, R.S., and Chen, W. (2019). Delayed Diagnosis of Crohn\u2019s Disease is common and associated with an increased risk of disease complications. Crohn\u2019s Colitis Congr., in press.","DOI":"10.1053\/j.gastro.2019.01.081"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/M17-3365","article-title":"High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes","volume":"169","author":"Wharam","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2017.75.2501","article-title":"Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment","volume":"36","author":"Wharam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MLR.0000000000000008","article-title":"Impact of a high-deductible health plan on outpatient visits and associated diagnostic tests","volume":"52","author":"Reddy","year":"2014","journal-title":"Med. Care"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11606-009-1184-5","article-title":"Consumer awareness and strategies among families with high-deductible health plans","volume":"25","author":"Lieu","year":"2010","journal-title":"J. Gen. Intern. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00415-010-5560-1","article-title":"Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study)","volume":"257","author":"Arbizu","year":"2010","journal-title":"J. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Moon, C.M., Jung, S.A., Kim, S.E., Song, H.J., Jung, Y., Ye, B.D., Cheon, J.H., Kim, Y.S., Kim, Y.H., and Kim, J.S. (2015). Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn\u2019s Disease Patients: Results from the CONNECT Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144390"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/CEG.S12596","article-title":"Irritable bowel syndrome: Diagnostic approaches in clinical practice","volume":"3","author":"Burbige","year":"2010","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Brownlee, W.J. (2018). Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?. Neurology.","DOI":"10.1212\/WNL.0000000000006584"},{"key":"ref_154","unstructured":"Olek, M.J., and Howard, J. (2018). Evaluation and Diagnosis of Multiple Sclerosis in Adults, UptoDate."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1212\/WNL.0000000000003152","article-title":"The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study","volume":"87","author":"Solomon","year":"2016","journal-title":"Neurology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458508096878","article-title":"Differential diagnosis of suspected multiple sclerosis: A consensus approach","volume":"14","author":"Miller","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2012-eular.1486","article-title":"SP0011 Difficult Cases: Seronegative rheumatoid arthritis","volume":"71","author":"Sokka","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3899\/jrheum.130328","article-title":"Rheumatic and musculoskeletal features of Whipple disease: A report of 29 cases","volume":"40","author":"Meunier","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.13140","article-title":"Systematic review: Whipple\u2019s disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors","volume":"41","author":"Marth","year":"2015","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/rheumatology\/keh059","article-title":"Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years","volume":"43","author":"James","year":"2004","journal-title":"Rheumatology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.amjmed.2011.05.031","article-title":"Opioid use, misuse, and abuse in patients labeled as fibromyalgia","volume":"124","author":"Fitzcharles","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/0253-7613.103235","article-title":"The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review","volume":"44","author":"Chandrashekara","year":"2012","journal-title":"Indian J. Pharm."},{"key":"ref_163","first-page":"s151","article-title":"Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management","volume":"22","author":"Owens","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_164","first-page":"s51","article-title":"Report: Economic implications of inflammatory bowel disease and its management","volume":"22","author":"Mehta","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_165","unstructured":"Ollendorf, D.A., Chapman, R., Pearson, S.D., Kumar, V., Agboola, F., Synnott, P., Liu, S., Segel, C., Khan, S., and Campbell, J. (2017). Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, Institute for Clinical and Economic Review, Comparative Effectiveness Public Advisory Council."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12325-015-0256-7","article-title":"A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases","volume":"32","author":"Vangeli","year":"2015","journal-title":"Adv. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ajg.2015.207","article-title":"Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn\u2019s Disease in the United States","volume":"111","author":"Park","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","article-title":"Systematic review: The costs of ulcerative colitis in Western countries","volume":"31","author":"Cohen","year":"2010","journal-title":"Aliment Pharm. Ther."},{"key":"ref_169","first-page":"42","article-title":"Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States","volume":"10","author":"Lee","year":"2017","journal-title":"Am. Health Drug Benefits"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3111\/13696998.2012.727930","article-title":"Estimating the economic benefits of positive shifts in fibromyalgia severity: An exploratory analysis based on modeling of clinical trial data of pregabalin","volume":"16","author":"Cappelleri","year":"2013","journal-title":"J. Med. Econ."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1572-0241.2003.07296.x","article-title":"Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective","volume":"98","author":"Longstreth","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for inflammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2018","journal-title":"Aliment Pharm. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.22895","article-title":"Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis","volume":"68","author":"Jalal","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_175","first-page":"23","article-title":"Costs of Care for Irritable Bowel Syndrome in Managed Care","volume":"7","author":"Ricci","year":"2000","journal-title":"J. Clin. Outcomes Manag."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2106\/JBJS.N.00802","article-title":"The incidence of upper and lower extremity surgery for rheumatoid arthritis among Medicare beneficiaries","volume":"97","author":"Waljee","year":"2015","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1526-4637.2012.01450.x","article-title":"A model to identify patients at risk for prescription opioid abuse, dependence, and misuse","volume":"13","author":"Rice","year":"2012","journal-title":"Pain Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2106\/JBJS.16.00019","article-title":"Effects of the Length of Stay on the Cost of Total Knee and Total Hip Arthroplasty from 2002 to 2013","volume":"99","author":"Molloy","year":"2017","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: Comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharm. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3899\/jrheum.170001","article-title":"Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis","volume":"45","author":"Young","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_181","first-page":"84","article-title":"Compliance and Cost of Biologic Therapies for Rheumatoid Arthritis","volume":"9","author":"Bonafede","year":"2017","journal-title":"Am. J. Pharm. Benefits"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1533-2500.2010.00431.x","article-title":"Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine","volume":"11","author":"Zhao","year":"2011","journal-title":"Pain Pract."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"key":"ref_184","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1007\/s00415-018-9048-8","article-title":"2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes","volume":"265","author":"Gaetani","year":"2018","journal-title":"J. Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_187","first-page":"235","article-title":"The clinical and economic burden of chronic obstructive pulmonary disease in the USA","volume":"5","author":"Guarascio","year":"2013","journal-title":"Clin. Outcomes Res."},{"key":"ref_188","unstructured":"Feldman, B. (2019, March 05). Reversing the Invisible Epidemic of Autoimmune Disease. Available online: https:\/\/drbonnie360.com\/resources\/reversing-the-invisible-epidemic-of-autoimmune-disease\/."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/4\/493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:44:43Z","timestamp":1760186683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/4\/493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":188,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["jcm8040493"],"URL":"https:\/\/doi.org\/10.3390\/jcm8040493","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]}}}